MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts
Open Access
- 26 October 2009
- journal article
- Published by Rockefeller University Press in The Journal of cell biology
- Vol. 187 (3), 429-442
- https://doi.org/10.1083/jcb.200904049
Abstract
Cancer-expressed anti-apoptotic protein BCL-2 is stable, whereas MCL-1 undergoes proteasome-dependent degradation in response to chemotherapeutic agents.Keywords
This publication has 38 references indexed in Scilit:
- Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesisCell Death & Differentiation, 2009
- MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL familyOncogene, 2009
- In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomasProceedings of the National Academy of Sciences of the United States of America, 2008
- A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradationThe Journal of cell biology, 2008
- Dissecting eIF4E action in tumorigenesisGenes & Development, 2007
- Structural insights into the degradation of Mcl-1 induced by BH3 domainsProceedings of the National Academy of Sciences of the United States of America, 2007
- Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737JCI Insight, 2007
- c-Myc Sensitization to Oxygen Deprivation-induced Cell Death Is Dependent on Bax/Bak, but Is Independent of p53 and Hypoxia-inducible Factor-1Online Journal of Public Health Informatics, 2004
- Cell Death: Critical Control PointsCell, 2004
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985